Accomplishments in 2007 in the management of hepatobiliary cancers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.Oncotarget · 2017
   Article
2. A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression.Cancer medicine · 2016
   Article
3. Quality of life and hepatocellular carcinoma.Journal of gastrointestinal oncology · 2014
   Review
4. Management of hepatocellular carcinoma: beyond sorafenib.Current oncology reports · 2012
   Review
5. In-hospital mortality after resection of biliary tract cancer in the United States.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2010
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract